Advertisement

Alternative and Internet Drugs that Affect Sexual Function

  • Jonathan Israel
  • Eric L. LabordeEmail author
Chapter
Part of the Contemporary Endocrinology book series (COE)

Abstract

The purpose of this book chapter is to better understand the role of alternative nonprescription medications and their effect on sexual function. We will also discuss the prevalence of counterfeit prescription medications and their impact on health. We will discuss where these drugs are being produced and how they are regulated by the federal government. The role of the Internet as a method of obtaining these medications also will be explored. The most common alternative medicines will be reviewed based on clinical research trials in terms of efficacy and side effects.

Keywords

Counterfeit phosphodiesterase type 5 inhibitor (PDE5i) Natural erectile medication Alternative erectile medication Erectile dysfunction Supplements for erectile dysfunction 

References

  1. 1.
    Wilt T, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA. 1998;280:1604.CrossRefPubMedGoogle Scholar
  2. 2.
    Blumenthal M, The American Botanical Council. The ABC, clinical guide to herbs. New York: Thieme; 2003. p. 383–5.Google Scholar
  3. 3.
    Kaptchuk T. Acupuncture: theory, efficacy and practice. Ann Intern Med. 2002;136:374.CrossRefPubMedGoogle Scholar
  4. 4.
    Barnes P, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States. Adv Data. 2004;343:1–19.PubMedGoogle Scholar
  5. 5.
    Gutierrez S, Ang-Lee M, Walker D, Zacny J. Assessing subjective and psychomotor effects of the herbal medication valerian in healthy volunteers. Pharmacol Biochem Behav. 2004;78:57–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med. 2001;135:594.CrossRefPubMedGoogle Scholar
  7. 7.
    Campbell N, Clark J, Stecher V, Thomas J, Callanan A, Donnelly B, Goldstein I, Kaminetsky J. Adulteration of purported herbal and natural sexual performance enhancement dietary supplements with synthetic phosphodiesterase type 5 inhibitors. J Sex Med. 2013;10:1842–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Newmaster S, Grguric M, Shanmughanandhan D, Ramalingam S, Ragupathy S. DNA bar coding detects contamination and substitution in North American herbal products. BMC Med. 2013;11:222.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Stoeckle M, Gamble C, Kirpeka R, Young G, Ahmed S, Little D. Commercial teas highlight plant DNA barcode identification successes and obstacles. Sci Rep. 2011;1:42.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Baker D, Stevenson D, Little D. DNA barcode identification of black cohosh herbal dietary supplements. J AOAC Int. 2012;9:1023–34.CrossRefGoogle Scholar
  11. 11.
    Etienne C. International Medical Products Anti-counterfeiting Taskforce (IMPACT). Counterfeit Drugs Kill! World Health Organization; 2008.Google Scholar
  12. 12.
    Ko R. Adulterants in Asian patent medicines. N Engl J Med. 1998;339:847.CrossRefPubMedGoogle Scholar
  13. 13.
    Hill H. Counterfeit medicines—how much of a risk to public health are they? Pharm J. 2005;275:520.Google Scholar
  14. 14.
    DHHS. Adverse event reporting for dietary supplements: an inadequate safety valve. US: office of the inspector general, HHS; 2001.Google Scholar
  15. 15.
    Marcus D, Grollman A. Botanical medicines—the need for new regulations. N Engl J Med. 2002;347:2073.CrossRefPubMedGoogle Scholar
  16. 16.
    Cracking counterfeit: counterfeit medicines—the scope of the problem. Ireland: Pfizer; 2010.Google Scholar
  17. 17.
    Thompson J, Banks I. European Alliance for Access to Safe Medicines. The counterfeiting superhighway. Eur Alliance Access Safe Med. 2008:1–32.Google Scholar
  18. 18.
    Ukens C. Pharmacists can help stop counterfeit drugs. Drug Topics. 2004;148:31.Google Scholar
  19. 19.
    Dorsey P, Hellstrom W. The illicit sale of medications for the treatment of erectile dysfunction. Medscape Urol. 2007:1–8.Google Scholar
  20. 20.
    US Food and Drug Administration. FDA targets illegal online pharmacies in globally coordinated action. FDA News Release. 2014. Web.Google Scholar
  21. 21.
    Stecher V, Jackson G, Banks I, Arver S. Analysis of pharmaceuticals seized by authorities for suspicion of being counterfeit viagra (Sildenafil Citrate). Eur Soc Sexual Med. 2009:1.Google Scholar
  22. 22.
    Venhuis B, Barends D, Zwaagstra M, de Kaste D. Recent developments in counterfeits and imitations of viagra, Cialis and Levitra: a 2005–2006 update. RIVM Rep. 2007:1–55.Google Scholar
  23. 23.
    Megget K. The “global disaster” of fake internet pharmacies. pharmatechnologist.com. Web. 19 July 2007. Accessed 2 Mar 2015.Google Scholar
  24. 24.
    Catizone C. Counterfeit drugs and states’ efforts to combat the problem. J Pharm Pract. 2006;19:165–70.CrossRefGoogle Scholar
  25. 25.
    Jackson G, Arver S, Banks I, Strecher V. Counterfeit PDE-5i pose significant safety risk. Int J Clin Pract. 2010;64:497–504.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Yun T. Panax ginseng—a non-organ-specific cancer preventive? Lancet Oncol. 2001;2:49–55.CrossRefPubMedGoogle Scholar
  27. 27.
    Choi Y, Rha K, Choi H. In vitro and in vivo experimental effect of Korean red ginseng on erection. J Urol. 1999;162:1508–11.CrossRefPubMedGoogle Scholar
  28. 28.
    Jang D, Lee M, Byung-Cheul S, Ernst E. Red ginseng for treating erectile dysfunction: a systematic review. Br J Clin Pharmacol. 2008;66:444–50.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Hong B, Ji Y, Hong J, Nam K, Ahn T. A double-blind crossover study evaluating the efficacy of Korean red ginseng in patients with erectile dysfunction: a preliminary report. J Urology. 2002;168:2070–3.CrossRefGoogle Scholar
  30. 30.
    Choi H, Choi Y, Kim J. Penile blood change after oral medication of Korean red ginseng in erectile dysfunction patients. J Ginseng Res. 2003;27:165–70.CrossRefGoogle Scholar
  31. 31.
    de Andrade E, de Mesquita A, Claro Jde A, de Andrade P, Ortiz V, Paranhos M. Study of the efficacy of Korean Red Ginseng in the treatment of erectile dysfunction. Asian J Androl. 2007;9:241–4.CrossRefPubMedGoogle Scholar
  32. 32.
    Kim S, Paick S. Clinical efficacy of Korean red ginseng on vasculogenic impotent patients. Korean J Androl. 1999;17:23–8.Google Scholar
  33. 33.
    Horny Goats Weed. Herb Wisdom. Hallnet Ltd, n.d. Accessed 1 Mar 2015.Google Scholar
  34. 34.
    Xu H, Huang Z. Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro. Vascul Pharmacol. 2007;47:18–24.CrossRefPubMedGoogle Scholar
  35. 35.
    Ning H, Xin Z, Lin G, Banie L, Lue T, Lin C. Effects of icariin on phosphodiesterase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cells. Urology. 2006;68:1350–4.CrossRefPubMedGoogle Scholar
  36. 36.
    Shindel A, Xin Z, Lin G, Fandel T, Huang Y, Banie L, Breyer B, Garcia M, Lin C, Lue T. Erectogenic and neurotrophic effects of icariin, a purified extract of horny goat weed (Epimedium spp.) in vitro and in vivo. J Sex Med. 2010;7:1518–28.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ye L, Chen J, Liu S. Pharmacokinetics of icariin in rats. Chin Pharmaceut J. 1999;34:33–6.Google Scholar
  38. 38.
    Yang W, Yu X, Chen X, Zhang L, Lu C, Zhao Y. Pharmacokinetics and tissue distribution profile of icariin propylene glycol-liposome intraperitoneal injection in mice. J Pharm Pharmacol. 2012;64:190–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Partin J, Pushkin Y. Tachyarrhythmia and hypomania with horny goat weed. Psychosomatics. 2004;45:536–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Goldberg M, Roberston D. Yohimbine; a pharmacological probe for the study of the a2-adrenoreceptor. Pharmacol Rev. 1983;35:143–80.PubMedGoogle Scholar
  41. 41.
    Porst H, Burnett A, Brock G, Bhanem H, Giuliano F, Glina S, Hellstrom W, Martin-Morales A, Salonia A, Sharlip I. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10:130–71.CrossRefPubMedGoogle Scholar
  42. 42.
    Simonsen U, Prieto D, Hernandez M, Saenz de Tejada I, Garcia-Sacristan A. Prejunctional alpha 2-adrenoceptors inhibit nitrergic neurotransmission in horse penile resistance arteries. J Urol. 1997;157:2356–60.CrossRefPubMedGoogle Scholar
  43. 43.
    Owen J, Nakatsu S, Fenemore J, Condra M, Surridge D, Morales A. The pharmacokinetics of yohimbine in man. Eur J Clin Pharmacol. 1987;32:577–82.CrossRefPubMedGoogle Scholar
  44. 44.
    Guthrie S, Hariharan M, Grunhaus L. Yohimbine bioavailability in humans. Eur J Clin Pharmacol. 1990;39:409–11.CrossRefPubMedGoogle Scholar
  45. 45.
    Montague D, Barada J, Belker A, Levine L, Nadig P, Roehrborn C, Sharlip I, Bennett A. Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. J Urol. 1996;156:11.Google Scholar
  46. 46.
    Adeniyi A, Brindley G, Pryor J, Ralph D. Yohimbine in the treatment of orgasmic dysfunction. Asian J Androl. 2007;9:403–7.CrossRefPubMedGoogle Scholar
  47. 47.
    Efsa, ANS Panel (EFSA Panel on Food Additives and Nutrient Sources Added to Food). Scientific Opinion on the evaluation of the safety in use of Yohimbe (Pausinystalia yohimbe (K. Schum.) Pierre ex Beille). EFSA J. 2013;11:46.Google Scholar
  48. 48.
    National Center for Complementary and Alternative Medicine. Herbs at a glance: Yohimbe. United States department of health and human services. July 2012. Accessed March 2015.Google Scholar
  49. 49.
    Gonzales G. Ethnobiology and ethnopharmacology of Lepidium meyenii(Maca), a plant from the peruvian highlands. Evid Based Complement Alternat Med. 2012:1–10.Google Scholar
  50. 50.
    Clement C, Diazgrados D, Avula B, Kahn I, Mayer A, Aguirre D, Manrique I, Kruezer M. Influence of colour type and previous cultivation on secondary metabolites in hypocotyls and leaves of maca (Lepidium meyenii Walpers). J Sci Food Agric. 2010;90:861–9.PubMedGoogle Scholar
  51. 51.
    Zheng B. Effect of a lipidic extract from Lepidium meyenii on sexual behavior in mice and rats. Urology. 2000;55:598–602.CrossRefPubMedGoogle Scholar
  52. 52.
    Brooks N, Wilcox G, Walker K, Ashton J, Cox M, Stojanovska L. Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content. Menopause. 2008;15:1157–62.CrossRefPubMedGoogle Scholar
  53. 53.
    Gonzales G, Cordova A, Vega K, Chung A, Villena A, Gonez C, Castillo S. Effect of Lepidium meyenii (MACA) on sexual desire and its absent relationship with serum testosterone levels in adult healthy men. Andrologia. 2002;34:367–72.CrossRefPubMedGoogle Scholar
  54. 54.
    Stone M, Ibarra A, Roller M, Zangara A, Stevenson E. A pilot investigation into the effect of maca supplementation on physical activity and sexual desire in sportsmen. J Ethnopharmacol. 2009;126:574–6.CrossRefPubMedGoogle Scholar
  55. 55.
    Ernst E, Posadzki P, Lee M. Complementary and alternative medicine (CAM) for sexual dysfunction and erectile dysfunction in older men and women: an overview of systematic reviews. Maturitas. 2011;70:37–41.CrossRefPubMedGoogle Scholar
  56. 56.
    Zenico T, Cicero A, Valmorri L, Mercuriali M, Bercovich E. Subjective effects of Lepidium meyenii extract on well-being and sexual performances in patients with mild erectile dysfunction: a randomised, double-blind clinical trial. Andrologia. 2009;41:95–9.CrossRefPubMedGoogle Scholar
  57. 57.
    Piacente S, Carbone V, Plaza A, Zampelli A, Pizza C. Investigation of the tuber constituents of maca (Lepidium meyenii Walp). J Agric Food Chem. 2002;50:5621–5.CrossRefPubMedGoogle Scholar
  58. 58.
    APSSA. From the French Agency of Sanitary Security on foods relative to the risk assessment for health by consuming pulverized maca roots or as alimentary supplement. AfssaSaisine 2004-SA-0155 2004:1–3.Google Scholar
  59. 59.
    Schmitt C, Dirsch V. Modulation of endothelial nitric oxide by plant-derived products. Nitric Oxide. 2009;21:77–91.CrossRefPubMedGoogle Scholar
  60. 60.
    Ude C, Schubert-Zsilavecz M, Wurglics M. Ginkgo biloba extracts: a review of the pharmacokinetics of the active ingredients. Clin Pharmacokinet. 2013;52:727–49.CrossRefPubMedGoogle Scholar
  61. 61.
    Kang B, Lee S, Kim M, Cho M. A placebo controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol. 2002;17:279–84.CrossRefPubMedGoogle Scholar
  62. 62.
    Wheatley D. Triple-blind, placebo-controlled trial of Gingko biloba in sexual dysfunction due to antidepressant drugs. Hum Psychopharmacol. 2004;19:545–8.CrossRefPubMedGoogle Scholar
  63. 63.
    National Institutes of Health. Ntp technical report on the toxicology and carcinogenesis studies of Ginkgo biloba (cas no. 90045-36-6) in f344/n rats and b6c3f1/n mice(gavage studies). NIH Publication No. 13-5920. 2013:184.Google Scholar
  64. 64.
    Hardigree A, Epler J. Comparative mutagenesis of plant flavonoids in microbial systems. Mutat Res. 1978;58:231–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Birks J, Grimley E, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2002;4. Article ID CD003120.Google Scholar
  66. 66.
    Fugh-Berman A. Herb-drug interactions. Lancet. 2000;355:134–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Leistner E, Drewke C. Ginkgo biloba and ginkgotoxin. J Nat Prod. 2010;73:86–92.CrossRefPubMedGoogle Scholar
  68. 68.
    Shamloul R. Natural aphrodisiacs. J Sex Med. 2010;7:39–49.CrossRefPubMedGoogle Scholar
  69. 69.
    Waynberg J. Yohimbine vs. muira puama in the treatment of sexual dysfunction. Am J Nat Med. 1994;1:8–9.Google Scholar
  70. 70.
    Cavallini G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology. 2004;62:641–6.CrossRefGoogle Scholar
  71. 71.
    University of Maryland Medical Center. Carnitine (l-Carnitine). University of Maryland Medical Center (UMMC). March 2011. Accessed March 2015.Google Scholar
  72. 72.
    Komori K, Tsujimura A, Takao T, Matsuoka Y, Miyagawa Y, Takada S, Honomura N, Okuyama A. Nitric oxide synthesis leads to vascular endothelial growth factor synthesis via the NO/cyclic guanosine 3′,5′-monophosphate (cGMP) pathway in human corpus cavernosal smooth muscle cells. J Sex Med. 2008;5:1623–35.CrossRefPubMedGoogle Scholar
  73. 73.
    Morris Jr S. Enzymes of arginine metabolism. J Nutr. 2004;134:2743S–7.PubMedGoogle Scholar
  74. 74.
    Chen J, Wollman Y, Chernichovsky T, Iaina A, Sofer M, Matzkin H. Effect of oral administration of high-dose nitric oxide donor l-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int. 1999;83:269–73.CrossRefGoogle Scholar
  75. 75.
    Klotz T, Mathers M, Braun M, Bloch W, Engelmann U. Effective of oral l-arginine in first line treatment of erectile dysfunction in a controlled crossover study. Urol Int. 1999;62:220–3.CrossRefGoogle Scholar
  76. 76.
    Cormio L. Oral l-citrulline supplementation improves erection hardness in men with mild erectile dysfunction. Urology. 2011;77:119–22.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of UrologyOchsner Medical CenterNew OrleansUSA

Personalised recommendations